CENTENE CORP

Centene's capital structure shows a debt-to-equity ratio of 0.76, indicating moderate leverage. The company maintains strong liquidity with $21.26 billion in cash and equivalents, and a current ratio of 1.12, though this is near the minimum comfort range. Free cash flow of $4.17 billion in Q1 2026 supports operational flexibility and potential for shareholder returns. Profitability metrics show a return on equity of 7.19% and return on assets of 1.9%, both below the industry median for managed healthcare. The operating margin of 4.17% (calculated from operating income of $1.86 billion on revenue of $44.66 billion) is also below the sector average, suggesting room for improvement in cost management and pricing power. Revenue is concentrated across four segments: Medicaid (58% of total revenue), Medicare (21%), Commercial (17%), and Other (4%). Medicaid operations are heavily dependent on government contracts, exposing the company to regulatory and policy risks. The geographic footprint is broad, with significant exposure to states like Missouri, Tennessee, and Florida, where premium revenues are a key driver. Outlook for FY 2026 shows revenue growth of 4.2% year-over-year, with a 3.1% increase expected in FY 2027. This growth is driven by Medicaid expansion and Medicare Advantage enrollment gains, though margin pressures from rising healthcare costs and regulatory changes remain a headwind. Risk factors include regulatory uncertainty, particularly around the ACA and eAPTCs, which could impact membership and profitability. The company also faces dilution risk from potential equity issuances, though current dilution potential is low. Recent impairment charges of $513 million after-tax in 2025 highlight asset risk from business transactions. Recent events include the adoption of ASU 2024-03, which will expand income statement disclosures, and a goodwill impairment charge related to the Magellan Health divestiture. These events underscore the company's exposure to accounting changes and strategic restructuring.